^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CJRB-101

    i
    Associations
    News

    Trials

    Company:
    CJ Biosci
    Drug class:
    Microbiome modulator
    Related drugs:
    Associations
    News

    Trials

    Apply
    Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer (NCT05877430)
    Phase 1/2
    CJ Bioscience, Inc.
    Recruiting
    Last update posted :
    12/18/2023
    Initiation :
    09/11/2023
    Primary completion :
    07/01/2026
    Completion :
    10/01/2027
    BRAF
    |
    PD-L1 expression • BRAF mutation • BRAF V600
    |
    Keytruda (pembrolizumab) • CJRB-101